- RecruitingPHASE2
A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
This study is testing a new medicine called Sutacimig for people with a rare bleeding condition called Factor VII Deficiency. It aims to see if it's safe and how well it works after one dose to help stop bleeding.
For: Congenital Factor VII DeficiencyUnited Kingdom - RecruitingPhase II
Study to test the safety and effectiveness of sutacimig for people with a rare bleeding condition called congenital factor VII deficiency
This study is testing a new medicine called sutacimig for people with a rare bleeding condition called congenital factor VII deficiency. It aims to see if sutacimig is safe and helps blood clot better. Participants will have one dose and be monitored for about 3 months.
For: Congenital coagulation factor VII deficiencyUnited Kingdom · England